MannKind Corp. and One Drop have signed an agreement to integrate MannKind’s BluHale accessory device into the One Drop platform, according to a statement from MannKind on Monday.
The Westlake Village biotech chose One Drop, a diabetes software company based in New York, for its AI-enabled glucose forecasts, predictive insights and an educational service recognized by the American Diabetes Association.
MannKind makes Afrezza, an inhalable insulin. Under the agreement, Afrezza users who have the BluHale accessory, which attaches to the inhaler and conveys real-time information about inhalation effort and insulin dose, will now have access to One Drop’s predictive tech.
“Earlier this year, One Drop announced clinical data that demonstrated using Afrezza with One Drop provided a significant improvement in A1C levels,” Michael Castagna, chief executive of MannKind, said in a statement. “We believe the future of diabetes management will increasingly depend on data collected on a smartphone that provides real time decision support insights that will help patients and providers achieve improved outcomes.”
Shares of MannKind (MNKD) dropped 6 cents, or 5 percent, on Monday to close at $1.12 on the Nasdaq.